Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | PLK1 | P53350 | 3/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ULK1 | O75385 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | STAT6 | P42226 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720894 | 0.84 | GABRP (0.42) | PGK1MAPTGAAALDH1A1KMT2A | |
| SCHEMBL1801333 | 0.83 | MAPT (0.41) | PGK1MAPTKMT2ACHRNA7 | |
| Fluoride SCHEMBL3339659 | 0.83 | GABRP (0.41) | PGK1MAPTGAAALDH1A1KMT2A | |
| SCHEMBL486056 | 0.82 | MAPT (0.40) | PGK1MAPTCASP1ALDH1A1KMT2A | |
| SCHEMBL3057584 | 0.81 | L3MBTL1 (0.40) | CYP1A2 | |
| SCHEMBL13189895 | 0.81 | GAA (0.38) | PGK1MAPTGAACYP2C9PLK1 | |
| SCHEMBL3060372 | 0.80 | KDR (0.48) | STAT6 | |
| SCHEMBL25142605 | 0.79 | CYP2C9 (0.41) | GAACYP2C9 | |
| SCHEMBL15635052 | 0.78 | MEN1 (0.42) | PGK1MAPTKMT2A | |
| SCHEMBL6221826 | 0.76 | GRM5 (0.45) | ALDH1A1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20120053209-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053209-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053209-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| EP-2411364-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109115-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109123-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NAMPT, NQO1, NNT | PGK1 807/4885MAPT 2632/4885GAA 645/4885 |
| US-20120053209-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NAMPT, NQO1, NADK | PGK1 822/4885MAPT 2535/4885GAA 559/4885 |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | PGK1 3129/4885MAPT 2785/4885GAA 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.